Tolremo raises €35.1M Series A round
20 September 2023· Basel, Switzerland· health, biotech, drug_discovery, oncology, small_molecule_therapeutics, epigenetics, b2b
The funding will be used to fund a Phase I trial for its lead candidate (TT125-802) in solid tumors and accelerate the company's lead program.
Investors
LeadBioMedPartners AG
Also participating
redalpineWille FinancePierre Fabre InvestAltos Ventures Management
About Tolremo
Stage
Series A
Headquarters
Basel, Switzerland
Founded
2017
Team Size
6–20
Sectors
healthbiotechdrug_discoveryoncologysmall_molecule_therapeuticsepigeneticsb2b